Last reviewed · How we verify
Obidoxim (OBIDOXIME)
Obidoxim (generic name: OBIDOXIME) is a obidoxime drug. It is currently in Phase 2 development for Organophosphate poisoning.
Obidoxim works by reactivating Acetylcholinesterase, an enzyme that breaks down acetylcholine, a neurotransmitter.
Obidoxim (OBIDOXIME) is a small molecule obidoxime drug that targets Acetylcholinesterase. It is used to treat Organophosphate poisoning. The commercial status of Obidoxim is unclear, and it is not FDA approved. Obidoxim has a half-life of 1.2 hours, but its bioavailability is unknown. It is owned by an unknown entity, originally developed by an unknown entity.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | OBIDOXIME |
|---|---|
| Drug class | obidoxime |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Think of acetylcholine like a key that unlocks muscles to move. When Organophosphate poisoning occurs, it blocks the key from working, causing muscles to become paralyzed. Obidoxim acts like a special tool that removes the blockage, allowing the key to work again and restoring muscle function.
Approved indications
- Organophosphate poisoning
Common side effects
Key clinical trials
- Assessing The Role Of Intravenous Lipid Emulsion As A Life Saving Therapy In Pesticides Toxicity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Obidoxim CI brief — competitive landscape report
- Obidoxim updates RSS · CI watch RSS
Frequently asked questions about Obidoxim
What is Obidoxim?
How does Obidoxim work?
What is Obidoxim used for?
What is the generic name of Obidoxim?
What drug class is Obidoxim in?
What development phase is Obidoxim in?
What does Obidoxim target?
Related
- Drug class: All obidoxime drugs
- Target: All drugs targeting Acetylcholinesterase
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Organophosphate poisoning
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing